Dr. Jeremy S. Kortmansky
Claim this profileYale University
Studies Colorectal Cancer
Studies Colon Cancer
6 reported clinical trials
18 drugs studied
Area of expertise
1Colorectal Cancer
Stage III
Stage IV
BRAF negative
2Colon Cancer
Stage III
Stage IV
BRAF negative
Affiliated Hospitals
Clinical Trials Jeremy S. Kortmansky is currently running
Pembrolizumab + Olaparib
for Pancreatic Cancer
This phase II trial studies whether adding pembrolizumab to olaparib (standard of care) works better than olaparib alone in treating patients with pancreatic cancer with germline BRCA1 or BRCA2 mutations that has spread to other places in the body (metastatic). BRCA1 and BRCA2 are human genes that produce tumor suppressor proteins. These proteins help repair damaged deoxyribonucleic acid (DNA) and, therefore, play a role in ensuring the stability of each cell's genetic material. When either of these genes is mutated, or altered, such that its protein product is not made or does not function correctly, DNA damage may not be repaired properly. As a result, cells are more likely to develop additional genetic alterations that can lead to some types of cancer, including pancreatic cancer. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Olaparib is an inhibitor of PARP, a protein that helps repair damaged DNA. Blocking PARP may help keep tumor cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy. The addition of pembrolizumab to the usual treatment of olaparib may help to shrink tumors in patients with metastatic pancreatic cancer with BRCA1 or BRCA2 mutations.
Recruiting1 award Phase 237 criteria
Chemotherapy Tailored by ctDNA Status
for Colon Cancer
This trial tests if a blood test for cancer DNA can help decide if colon cancer patients need more treatment after surgery. The test looks for cancer DNA in the blood to predict if the cancer might come back and to guide further treatment.
Recruiting1 award Phase 2 & 3
More about Jeremy S. Kortmansky
Clinical Trial Related6 years of experience running clinical trials · Led 6 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Jeremy S. Kortmansky has experience with
- Trastuzumab
- Pertuzumab
- Cetuximab
- Irinotecan Hydrochloride
- Savolitinib
- Capecitabine
Breakdown of trials Jeremy S. Kortmansky has run
Colorectal Cancer
Colon Cancer
Adenocarcinoma
Rectal Cancer
HER2 Gene Amplification
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Jeremy S. Kortmansky specialize in?
Jeremy S. Kortmansky focuses on Colorectal Cancer and Colon Cancer. In particular, much of their work with Colorectal Cancer has involved Stage III patients, or patients who are Stage IV.
Is Jeremy S. Kortmansky currently recruiting for clinical trials?
Yes, Jeremy S. Kortmansky is currently recruiting for 2 clinical trials in New Haven Connecticut. If you're interested in participating, you should apply.
Are there any treatments that Jeremy S. Kortmansky has studied deeply?
Yes, Jeremy S. Kortmansky has studied treatments such as Trastuzumab, Pertuzumab, Cetuximab.
What is the best way to schedule an appointment with Jeremy S. Kortmansky?
Apply for one of the trials that Jeremy S. Kortmansky is conducting.
What is the office address of Jeremy S. Kortmansky?
The office of Jeremy S. Kortmansky is located at: Yale University, New Haven, Connecticut 06520 United States. This is the address for their practice at the Yale University.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.